Niagen Bioscience, Inc. Releases 2025 Annual Report: Key Insights for Investors

LOS ANGELES, March 4, 2026 – Niagen Bioscience, Inc. (Nasdaq: NAGE), a life sciences company specializing in medicinal chemicals and botanical products, has released its annual report for the fiscal year ended December 31, 2025. This comprehensive 10-K filing provides a deep look into the company’s operational performance, financial condition, business segments, and key risks—offering crucial insights for current and prospective shareholders.

Key Highlights from the 2025 Annual Report

• Company Overview and Business Segments
  • Niagen Bioscience, formerly known as ChromaDex Corp., operates through several business segments: Consumer Products (with flagship product Tru Niagen^®), Ingredients, and a recently divested Analytical Reference Standards and Services segment.
  • The pharmaceutical segment is focused on developing a therapeutic candidate for rare advanced aging diseases and currently holds an exclusive patent portfolio for this molecule. No commercial sales or marketing activities have begun for the pharmaceutical segment; efforts remain in research and development.
• Financial Overview
  • As of June 30, 2025, the market value of common stock held by non-affiliates was approximately \$813.9 million, based on the Nasdaq closing price.
  • There were 80,080,488 shares of common stock outstanding as of March 3, 2026.
  • Niagen Bioscience is classified as a “Non-accelerated filer” and “Smaller reporting company,” and does not qualify as an emerging growth company.
  • The company has not paid cash dividends in the past and does not expect to pay cash dividends in the foreseeable future.
• Securities Information
  • Common Stock is listed on the Nasdaq Capital Market under the ticker symbol NAGE.
  • The company is in compliance with all current reporting requirements and has filed all necessary reports and data files with the SEC.

Potential Price Sensitive Information & Shareholder Considerations

• Business Dependency and Revenue Risks
  • Niagen’s future success is largely dependent on the sales of its flagship product, Tru Niagen^®. Any interruptions in key customer relationships or a decline in business with major customers could materially harm results and significantly impact share value.
  • The company’s performance is tightly linked to the wellness industry’s size and growth rate—any adverse changes in the market could have a material negative effect on Niagen’s financials.
  • Operating results may fluctuate significantly, leading to unpredictability and the risk of results falling below market expectations.
  • Historical operating losses persist, and Niagen warns it may need additional financing to meet future capital requirements. There is no guarantee the company will be able to raise sufficient capital on favorable terms or at all.
• Strategic Changes and Divestitures
  • The company has sold its Analytical Reference Standards and Services segment. The impact on revenue streams and capital allocation is a key consideration for shareholders, though details on the financial effect of the divestiture are not elaborated in the summary.
• Pharmaceutical Segment Outlook
  • The pharmaceutical segment remains in the research and development phase, with no commercial sales yet. The success of this segment depends on timely development, successful clinical trials, regulatory approvals, and the ability to secure contracts with FDA-registered facilities.
  • Any progress or setbacks in this segment could move the share price due to its potential for significant long-term value creation or risk.
• Regulatory and Legal Risks
  • Niagen is subject to stringent and evolving global privacy, data security, and regulatory compliance requirements. Any failure to comply could lead to material adverse effects on business operations, financial condition, or reputation.
  • Potential exists for product liability claims or class action litigation, which could increase costs and damage reputation.
  • There are also risks related to changing government regulation of the pharmaceutical, dietary supplement, and food industries, which could impact operations and demand for products.
  • The company highlights the possibility of becoming involved in securities class action litigation, which could divert management’s attention and harm business.
• Market and Capital Markets Risks
  • The market price of Niagen’s stock may be volatile and adversely affected by several factors, including the large number of outstanding options and unvested restricted stock units. Future sales of these shares could further pressure the share price.
  • Global market and economic conditions could impact financial condition and share price.
  • Any failure to establish and maintain effective internal controls over financial reporting could result in material misstatements and loss of investor confidence, potentially affecting share value.
• China Market Entry Risk
  • Niagen has a limited operating history in China. Its ability to develop successful sales channels in China is subject to legal and political uncertainties.

Additional Information for Investors

• Niagen Bioscience provides electronic copies of its filings, including the 10-K, on its investor relations website www.niagenbioscience.com and via the SEC’s EDGAR system.
• Portions of the company’s proxy statement (to be filed with the SEC in connection with the 2026 Annual Meeting of Stockholders) are incorporated by reference into the 10-K and will be available within 120 days of the fiscal year end.

Summary of Risks for Shareholders

• Interruption in customer relationships or declines in major accounts
• Market and economic downturn risks
• Dependence on a single flagship product for growth
• Need for ongoing marketing effectiveness and efficiency
• Significant competition from larger, better-resourced competitors
• History of operating losses and potential future capital needs
• Risks associated with product liability, regulatory compliance, and class action litigation
• Potential volatility in share price from market, regulatory, or operational developments

Conclusion

Niagen Bioscience’s 2025 annual report should be considered material reading for investors. The company’s heavy reliance on Tru Niagen^®, ongoing R&D in its pharmaceutical segment, recent divestiture of a business unit, and a history of operating losses present both risks and opportunities. Regulatory and legal risks, as well as the potential for capital markets volatility, are important considerations for valuation and share price movement. Investors are encouraged to review the full risk factors and financial notes contained in the official filing and to monitor for updates as the company pursues its strategic initiatives.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers should consult their own financial or legal advisors before making any investment decisions. The information here is drawn from Niagen Bioscience’s official SEC filings and is believed to be accurate as of the date of publication, but no guarantee is made as to its accuracy or completeness. Past performance is not indicative of future results.

View Niagen Bioscience, Inc. Historical chart here